Clinical Observation Of Tonifying Kidney And Activating Blood Decoction In Treating Parkinson’s Disease With Kidney Deficiency And Blood Stasis

Objective:The clinical efficacy and drug safety of Tonifying kidney and activating blood decoction were evaluated,through the clinical study on Tonifying kidney and activating blood decoction combined with Western medicine in the treatment of Parkinson’s disease(PD)with kidney deficiency and blood stasis,which provided clinical reference for the treatment of PD with Traditional Chinese Medicine(TCM)and western medicine.Methods: The outpatient and inpatient patients were selected from the Inpatient department of encephalopathy of the First Affiliated Hospital of Guangxi University of Chinese Medicine since March 2019 to October2019,who met the diagnosis of tremor syndrome with kidney deficiency and blood stasis in TCM and PD in western medicine.According to the inclusion and exclusion criteria,a total of 60 patients were enrolled.According to the random number table method,they were divided into treatment group and control group,with 30 patients in each group.The control group was treated with western medicine alone,while the treatment group was treated with western medicine plus Tonifying kidney and activating blood decoction for 4weeks.During the treatment,the two groups did not change the anti-Parkinson’s disease medication regimen.Before and after treatment,the United Parkinson’s disease rating scale part III(UPDRSIII),39-item Parkinson’s disease questionnaire(PDQ-39)and TCM syndrome scoring scale of patients in the two groups were uniformly scored by two prescribed neurologists.Before and after treatment,the serum levels of uric acid(UA)and homocysteine(Hcy)in patients serum were tested.At the same time,the three major routine,liver and kidney function and electrocardiogram were monitored,and the adverse drug reactions were observed.All clinical datas were statistically analyzed using SPSS19.0 statistical software to evaluate the efficacy of the study results.Results: The clinical trial was carried out in strict accordance with the research protocol,and a total of 60 cases were collected.No cases were lost.1.Before treatment,age,gender,course of disease,dosage of drugs,modified Hoehn&Yahr rating,UPDRSIII score,PDQ-39 score,TCM syndrome score and the serum levels of UA and Hcy of the two groups were compared,and the differences were not statistically significant(P>0.05).2.Motor function aspect:After treatment,UPDRSIII score of the two groups were significantly lower than before treatment,and the difference was statistically significant(P < 0.05).After treatment,UPDRSIII score of the treatment group were significantly lower than that of the control group,and the difference was statistically significant(P<0.05).3.Quality of life aspect:After treatment,the PDQ-39 score of the two groups was significantly lower than that before treatment,and the difference was statistically significant(P < 0.05).After treatment,the PDQ-39 score of the treatment group was significantly lower than that of the control group,and the difference was statistically significant(P<0.05).4.TCM syndrome score aspect: After treatment,the TCM syndrome score of the two groups was significantly lower than that before treatment,and the difference was statistically significant(P < 0.05).After treatment,the TCM syndrome score of the treatment group was significantly lower than that of the control group,and the difference was statistically significant(P<0.05).5.The serum levels of UA and Hcy aspect: After treatment,the serum level of UA in both groups was significantly higher than that before treatment,and the difference was statistically significant(P<0.05).The serum level of UA in the treatment group was significantly higher than that of the control group,and the difference was statistically significant(P < 0.05).After treatment,the serum level of Hcy in both groups was significantly lower than that before treatment,and the difference was statistically significant(P<0.05).The serum level of Hcy in the treatment group was significantly lower than that of the control group,and the difference was statistically significant(P<0.05).6.Clinical efficacy aspect: After the course of treatment,the total effective rate of the treatment group was 83.33%,while the total effective rate of the control group was 76.67%.The effective rate of the treatment group was significantly better than that of the control group,and the difference was statistically significant(P<0.05).7.Medication safety aspect:During the treatment,no abnormalities were found in the three major routine procedures,liver and kidney functions and electrocardiogram.There were no adverse reactions in the treatment group,and the medication safety level was level I.Conclusion:1.Tonifying kidney and activating blood decoction can improve the motor function and quality of life of PD patients,and has a good clinical effect in treating PD with kidney deficiency and blood stasis.2.The effect of Tonifying kidney and activating blood decoction in the treatment of PD may be related to the increase of serum UA level and the decrease of serum Hcy level,and its mechanism needs further study.3.The medicine of Tonifying kidney and activating blood decoction is safe.